ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Chroma Medicine has launched with $125 million in financing to develop epigenetic editing therapies. Chroma uses a version of CRISPR gene editing that turns genes on or off by changing methylation patterns on DNA rather than by changing the DNA code itself. “We think it is going to unlock a huge breadth of applications,” says CEO Catherine Stehman-Breen. The firm isn’t disclosing its lead programs. Chroma is based on the work of its six academic founders: Luke Gilbert, Keith Joung, David Liu, Angelo Lombardo, Luigi Naldini, and Jonathan Weissman.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X